PHYSIDIA ANNOUNCES MAJOR ACHIEVEMENTS FOR 2020
Physidia, the European leader in frequent home hemodialysis, announces exponential growth and major achievements for 2020
2020 confirms Physidia’s exceptional results in a fast-growing environment.
The company, specialized in development, production and commercialization of an innovative- and mobile home hemodialysis system, keeps its focus on providing innovations for improving safety and simplicity of dialysis therapies for end-stage renal disease patients at home.
Home hemodialysis has encountered an even higher increase of interest during the COVID-19 pandemic, as it allows patients to perform autonomous dialysis in a secure environment at home. Publications report that COVID contaminations are 50% lower for patients treated by home dialysis rather than in in-center facilities, and incentives were put in place in several countries for increasing home hemodialysis adoption.
Physidia has demonstrated its strong foundations during the COVID-19 crisis, as it succeeded not only to increase the capacity of delivering products and services during the period, but it also provided significant help to dialysis centers requiring equipment for treating COVID-19 positive patients in isolated rooms.
2020 results of the company have grown by 51%, reaching 16,75Million €. Physidia is now well-established in European countries, including its own subsidiaries in France and the United Kingdom and within its distributor markets. More than 600 patients are now treated with the S3 system, making Physidia the European leader in home hemodialysis.
To achieve these results and make itself ready for its future growth objectives, Physidia has reinforced its organization and hired about 15% new employees, bringing the total number to 60 employees. The headquarters of the company, together with the production unit, were extended. The companies’ headcounts were increased in all functions and Physidia has now the capacity to endorse its future developments, providing innovation, additional services and further sales growth.
Partnerships for developing home hemodialysis
In January 2021, Physidia and ELSAN group, a major player in the private healthcare sector in France, signed a partnership agreement for the development of home hemodialysis in the private hospitals of the group, proof of the increasing interest of the private sector in this therapy.
Furthermore, Physidia has signed partnerships with two major providers in renal therapies – Baxter and B. Braun. In April, Physidia and Baxter France SAS announced a co-promotion agreement to support homecare for dialysis patients in France. The objective of this agreement is to offer patients leaving peritoneal dialysis the opportunity to stay at home by receiving frequent hemodialysis using Physidia’s S3 system. In addition, Physidia and B. Braun have signed an agreement covering 3 European countries. In France, the Physidia – B. Braun partnership focuses on developing home therapy in private B. Braun Avitum clinics. In Czech Republic, B. Braun becomes the exclusive distributor of the S3 system, whereas in the United Kingdom, B. Braun will be the logistics partner of Physidia UK. Despite varying country objectives of this partnership, the common denominator is the shared belief that frequent home hemodialysis has to be made available more widely.
“Changing the paradigm of home hemodialysis requires partnerships between all stakeholders on the market. Physidia as well as its Partners are committed to providing the best home therapy options to dialysis patients and are committed to promote homecare for patients with kidney failure” says Steve Haupt, Vice-president of Physidia.
National and International recognition
Physidia’s achievements were rewarded at French- and European level. In February 2021, the French business journal Les Echos, publishing yearly the classification of the fastest growing companies in France, placed Physidia on the first position within the French healthcare companies, and in 110th position in the general ranking. In parallel, The Financial Times, published in March 2021, also ranked Physidia amongst the 500 fastest growing companies within all categories in Europe.
While 2020 was a year of exponential growth for Physidia despite the COVID, 2021 is expected to be the year of international expansion and continuous innovation for the French leader of home hemodialysis
Created in Angers (France) in 2011, Physidia developed and commercializes S³, the first system designed specifically for patients who need daily hemodialysis whilst ensuring their safety and comfort. This innovation is based on several technological breaking points, offering a robust, portable and connected device, whilst ensuring a treatment performed in total autonomy. The short treatment, which lasts in average 2 hours on a daily basis, can be performed at home in full autonomy without compromising the quality of the renal dialysis nor its safety. The system fully favors the patients’ social and professional reintegration, an approach which is impossible to consider for patients who must go to dialysis centers.
The company registered three patents for its hemodialysis system S³. The device and a part of the consumables are produced in France. Physidia is operating directly in France and The United Kingdom and through distributor partners in the rest of Europe. Since its origin, the principal ethos of the company has been innovation with exceptional service by providing comfort, freedom and security to every patient. https://www.physidia.com/
Renal failure and hemodialysis
End-stage renal disease (ESRD) is a severe, chronic disease impacting thousands of people in France. The conventional hemodialysis treatment (artificial kidney) implies three weekly 4-hour sessions at a healthcare facility, to which should be added waiting, recovery and transportation times.
Today representing 43,000 patients, the number of people who are given dialysis increases by 3% every year and costs around € 4bn a year to local governments. Physidia’s solution allows them to make significant economies, by reducing visits and/or transportation to healthcare centers for example.